Tardive Dyskinesia and Pimozide
by Dr A C Gibson (St Ann's Hospital, Canford Cliffs, Poole, Dorset) Tardive dyskinesia is a condition characterized by abnormal involuntary movements of the lower face and tongue which may spread to choreiform movements of the extremities and sometimes the trunk. Rarely it occurs spontaneously in elderly people, but the vast majority of persons so afflicted have been taking neuroleptic drugs for a period of months or years.
In a study of 374 outpatients receiving antipsychotic depot injections, the author was surprised by the rapidly increasing incidence of tardive dyskinesia (TD) which became apparent over a period of 3 years. The patients, whose original number was 450, were examined on 4 occasions at yearly intervals and Fig 1 shows the way in which TD became apparent. At the beginning of the second examination it was decided to classify the bucco-linguo-masticatory movements from Grades 1-3 as follows:
Grade 1: Infrequent lateral jaw movement, smacking movements of the lips, puckering and pouting and slight tongue movement, as evidenced by tongue occasionally distending cheek. Grade 2: Almost constant movements as above. Grade 3: Constant movements of lower face and tongue, associated with mouth opening and protrusion of tongue.
It will be seen from Fig 1 that the majority of cases were in Grade 1 and they were basically mild in degree. However, in view of the extensive literature on the subject and the apparent certainty that this is a progressive and (in the view of many others) an irreversible condition, it was decided that steps would have to be taken to change the treatment pattern that these patients were receiving.
Because all the patients had received oral neuroleptic drugs for a mean period of 10.6 years before they were put on to injections, there was no way of being sure that the depot preparations were no more than the final factor, so far as the development of TD was concerned. But in this connection may be mentioned the work of Curry (1971) whose study of chlorpromazine absorption and metabolism shows low plasma levels following oral administration due to varying degrees of absorption from the gut. Anderson et al. (1973) examining 97 chronic in-patient schizophrenics who were considered non-responders to oral chlorpromazine, showed 39 to have significantly lower plasma levels of unmetabolized chlorpro-mazine, so that there remains the strong suspicion that some chronic patients have developed their own defence against absorbing neuroleptic preparations and this is by-passed by giving them injections. There is general agreement that tardive dyskinesia is almost certainly due to hypersensitization of dopamine receptors due to prolonged neuroleptic medication and there was evidence in this group of patients that the longer they had been on injections, the more likely they were to develop TD.
Of the 84 patients who developed TD in one form or another 33 were selected, because at the time it was thought that they had sufficient insight into their condition to revert to oral medication. The drug that they were given was pimozide. In fact, of the whole group of 84 who showed abnormalities of movement of the lower face and tongue, 18 also showed choreiform movements of the extremities and of the 33 cases selected for pimozide administration, no less than 13 showed choreiform movements. Retrospectively, the author believes that he was influenced by this phenomenon without realizing it, having seen 4 out of 6 cases of drug-induced chorea (without facial involvement) clear up completely with pimozide.
Although patients with tardive dyskinesia usually deny that they have anything the matter with them, when they come to be filmed, say for the purposes of assessment, they will clench their teeth and if they have chorea, fold their arms tightly and wrap one leg around the other, obviously in order to try and hide their movements. The chorea seems more apparent to them than the abnormal mouth movements, with the result that in the author's view they are more likely to take tablets than are patients not so Bucco linguo masticatory syndrom afflicted, just as the schizophrenic with Parkinsonism will take his anticholinergic drugs.
Pimozide was chosen because there is a strong impression that patients who had received anticholinergic drugs in the past were more prone to develop TD (Kiloh et al. 1974) . It seemed logical that most neuroleptic drugs, almost all of which have some anticholinergic properties (and some, such as thioridazine, very considerable anticholinergic properties) were not the drugs of choice. But pimozide, being unique in that it has an antipsychotic action with virtually no anticholinergic action, seems most likely to help. Table 1 indicates the particulars of the 33 patients. Six were ini Grade 2, that is moderately severe and the other 27 were mild cases in Grade 1. Seven of them had shown evidence of the bucco-linguo-masticatory syndrome when first examined in 1974. There was no firm evidence as to how long they had been so afflicted, but the rest developed the condition during the ensuing years of examination, with the result that their treatment was started within a relatively short time of the onset of the condition.
Over a period of 6-18 months the results of the change to pimozide were dramatic so far as the TD was concerned, so that 29 out of the 33 patients lost their abnormal movements entirely or they were so little in evidence that had the observer not known they had been so afflicted, he would not have noticed the abnormality. This was true both of the lower face and mouth movements and of the chorea.
The remaining 4 patients, however, made no improvement and it is of consequence that 2 of the 29 before getting better, got worse. This suggests that the pimozide was not working because it was a more potent dopamine antagonist than fluphenazine or flupenthixol, but rather that it had some special attribute of its own. One case who had been taking the drug for 2 years had a sudden relapse of her tardive dyskinesia and it looked as if the substance might only have a temporary effect in controlling the condition, as has been reported in other neuroleptics. However, hospital admission revealed that she had elected to discontinue her tablets and restoration of pimozide, although it has not cured her, has produced rapid amelioration of her condition.
So far as control of the psychotic symptoms is concerned, of the 33 patients changed to pimozide Chorea  55  68  67  58  60  64  63   56   73  51  72  58  50  55  65  42  32  52  45  65  51  53  42  37  45  68  52  42  38  66  60  63  50 1976 1975 1974 1975 1974 1976 1974 1975 1976 1975 1975 1975 1975 1976 1975 1975 1975 1975 1974 1975 1975 1975 1975 1976 1976 1975 1975 1974 1974 1974 1975 1976 1975 1963 1964 1972 1961 1971 1969 1971 1972 1966 1973 1969 1970 1973 1971 1970 1971 1972 1973 1971 1971 1972 1972 1973 1970 1973 1971 1973 1973 1973 1970 1968 1973 1966 1966 The view that tardive dyskinesia is due to hypersensitization of the dopamine receptors must be an oversimplified one, because in the 84 patients affected in this series, 5 show concomitant Parkinsonism, a condition due to dopamine depletion. York found that following the administration of iontophoretic dopamine, 53 putamen neurones showed facilitation, while 37 neurones showed inhibition and McLennon & York (1967) have shown that the caudate nucleus contains 2 populations of neurones respectively inhibited or facilitated by dopamine.
It is therefore quite possible that one neuroleptic is less likely to produce the condition of TD than another and this relatively small number of cases treated with pimozide is described because the author wonders if the question of the anticholinergic effect of a particular neuroleptic in relation to this condition has been as fully explored as it might have been. There can, of course, be no certainty that as time passes the TD will not occur again in those patients apparently well controlled by pimozide. However, Kazamazuri et al. (1973) found that in a group of chronic psychotics with TD, in whom they replaced their current medication by 8 mg of haloperidol daily, the involuntary movements disappeared, to return in the majority within 12 weeks, whereas in the group described here, 22 patients have received pimozide for over 2 years without relapse, and all for over 1 year. Moreover, with increasing numbers of cases of schizophrenia leaving hospital and being maintained in the community, the presence of tardive dyskinesia becomes an increasingly important subject for the psychiatrist to consider, because what is acceptable in an institution in the way of abnormal movements may be socially completely disabling for those living in the outside world. There are also medico-legal issues to be considered with this condition and I doubt if it would be easy to convince a court of law of the wisdom of continuing with the particular neuro-leptic drug that the patient happened to be receiving at the time that he developed his tardive dyskinesia.
Note added inproof
The patients were reassessed 12 months after the original investigation. Of the 29 patients whose tardive dyskinesia had virtually disappeared with the use of pimozide, 19 were found to show the condition in a mild form with constant, though slight movements of the lower face and tongue. In 9 of the other 10 who had pimozide discontinued for a period of 5 weeks to see if the dyskinesia had disappeared, it was found still to be apparent.
DISCUSSION
Professor S Hirsch (London) thought it important to mention that pimozide itself was not without its dangers. He remembered a young patient transferred from depixol to pimozide who started mild facial-lingual dyskinesias within a period of weeks or months. When the drug was discontinued the effect disappeared. He had never published this finding.
Dr Gibson said that he had scanned the literature trying to find any reference to pimozide causing tardive dyskinesia and the fact that he could find no such reference was one of his reasons for choosing it.
In answer to the Chairman's question about the onset of the condition, he said it was possible for it to appear within 4 months, but in the vast majority of cases it come on only within years of starting medication.
Dr B Alapin (St Albans) said that Dr Gibson's data showed that he had only 5 patients below the age of 50. Of the 5 patients showing Grade 2 changes, 4 were over 60 and 3 of the 4 who did not react to a change of medication were over 60. Thus, the effect of age was important.
He also wished to emphasize the question of the compound that was used. In one German series, 1500 patients with tardive dyskinesia had been found, of whom a third had been treated for a long time. The reason for their complaint was the use of butaperazine, an unpleasant major tranquillizer which he had rapidly abandoned because it was always connected with side effects. As to pimozide, he questioned whether even this drug at dosages of 8 mg was quite safe. Certainly he did not think that it would be at higher dosages, because he had observed Parkinsonian side effects with even smaller quantities.
Dr Gibson said that as to age, it was well known that these cases classically occurred in people in their 50s and 60s. That was simply a matter of observation.
As to side effects, he would not be very concerned with Parkinsonian effects which were controllable with appropriate medication. Clearly, he could not guarantee that the patients would remain free of tardive dyskinesia for the next 10 years. However, they had certainly done better than people who had been treated in other ways.
Dr Theofilopoulos (Liverpool) was somewhat apprehensive of the optimism expressed about pimozide removing tardive dyskinesia. Most of the literature, particularly from America, tended to indicate that once tardive dyskinesia set in it did not recede. In addition, post-mortem examinations suggested irreversible damage to the dopaminergic neurones in the brain. He therefore had some anxiety about doctors using neuroleptic agents indiscriminately in the hope that if tardive dyskinesia set in, pimozide might alleviate it.
Dr Gibson said that since pimozide was not commercially available in the USA they had little experience of its use in this condition. However, he agreed with the questioner. Thousands of words had been written on the irreversibility of tardive dyskinesia which was why he had brought a film to show the effects he had obtained. But there certainly was a point of no return. Most published work had been done on chronic, institutionalized patients and only rarely was it known for how long they had had the condition.
He firmly believed that patients on neuroleptic therapy should be closely monitored and treated appropriately if dyskinesia appeared. It was not necessary to give them pimozide. The neuroleptic could be reduced or changed, or a drug holiday given. Cases reported in the literature tended to be those of very long standing.
Dr L L Iversen (Cambridge) commented on the pharmacological rationale for choosing pimozide. Dr Gibson had chosen the drug in the belief that it was one of the few neuroleptics practically devoid of antimuscarinic action. However, that was not his conclusion from testing the drug on a CNS muscarinic receptor binding assay and recent work frorn the United States also suggested that pimozide was a rather potent antimuscarinic agent. The ratio of its anticholinergic to antidopamine activity was in the order of 1:1, whereas clozapine and thioridazine were the only 2 common neuroleptic agents known to be more potent as anticholinergics than as antidopaminergics. The 2 depot drugs that Dr Gibson had used and which appeared to be inducing tardive dyskinesias, i.e. flupenthixol and fluphenazine, were practically devoid of any anticholinergic properties. In that sense they were 'pure' drugs. Dr Gibson had introduced one which was not 'pure'. It would be of the greatest value to know which features were important in determining liability to induction of tardive dyskinesia or in determining response to treatment of that symptom. However, he did not believe that they had that information.
Dr Lader (Chairman) wondered whether this might not be another example of serendipity.
Dr U A Siddiqui (Durham) said that apart from the age effect in tardive dyskinesia, the literature also suggested that the majority of cases were female, even with ratios as high as 5:1. This did not give much support for the dopamine theory either.
Dr Gibson said that the sex ratio of those who developed tardive dyskinesia was exactly the same as that of the entire series. More patients with schizophrenia were female than male.
